Information Provided By: 
Fly News Breaks for May 3, 2018
SRDX
May 3, 2018 | 10:13 EDT
Barrington analyst Michael Petusky raised his price target for Surmodics to $43 following the company's better than expected Q2 results. The analyst's sum-of-the parts methodology assigns $22.50 per share for the core business, $15.25 for the SurVeil DCB program with Abbott and adds $5.25 per share for the net cash on the balance sheet. He keeps an Outperform rating on the name.
News For SRDX From the Last 2 Days
There are no results for your query SRDX
